Available and Emerging Treatment Options in IDH-Mutant and FLT3-Mutant AML

In this downloadable slideset, Eytan M. Stein, MD, provides expert insights and guidance on individualizing treatment for patients with AML with FLT3 or IDH1/2 mutations.
Eytan M. Stein, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 3.77 MB
Released: May 31, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Agios Pharmaceuticals
Boston Biomedical, Inc.
Celgene Corporation
Daiichi Sankyo, Inc.

Related Content

Latest evidence on effective management of chronic lymphocytic leukemia (CLL) using BTK inhibitors in this video from Clinical Care Options (CCO)

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: September 16, 2020 Expired: September 15, 2021

From Clinical Care Options (CCO), expert commentary by Dr Richard Finn on the use of atezolizumab plus bevacizumab for advanced HCC

Richard Finn, MD Released: September 15, 2020

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on immunotherapy for HCC

person default Lipika Goyal Goyal, MD, MPhil Amit G. Singal, MD, MS Released: September 14, 2020

Nicole Lamanna, MD, on modifying CLL treatment during COVID-19 pandemic, IVIg as COVID-19 prophylaxis, and the role of BTK inhibition, from CCO

Nicole Lamanna, MD Released: September 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?